In this quarterly strategy report, we look to evaluate where we are with regards the bull market conditions, and where those indicators might be headed, factoring in the downside risks, from Trump tariffs and the US economy, BoJ actions, Japanese earnings and valuations.
When the BoJ raised rates in March, it had been 17 years since it had last done so, though the world was very different then. While the July rate hike was unlikely to move the economic needle, the question now is what else might follow the subsequent financial market maelstrom. Pelham Smithers discusses the outlook for Japan’s macro environment, what new fiscal policies the new PM might introduce, how the BoJ might react and the all-important trend in corporate earnings. This then leads us to...
We review GNI Group, a small but fast-growing drug platform company. It currently has one sizable at-market drug [Etuary™ for IPF in China], a potential multi-market blockbuster in Phase III, and an interesting platform. EV/OP for FY24 is exceptionally low, at 6.1x.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
TOKYO--(BUSINESS WIRE)-- GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced positive results from the initial analysis of Phase II clinical trial of the F351 drug candidate for liver fibrosis. The trial was a randomized, double-blind, placebo-controlled, multi-center, dose escalation study assessing the safety and efficacy of F351 for Hepatic Fibrosis in Chronic Viral Hepatitis B patients in China. The Phase II study randomized 168 patients into 4 dose-escalating groups (placebo; 60 mg/tid; 90 mg/tid; and 120 mg/tid) with a primary end...
TOKYO--(BUSINESS WIRE)-- GNI Group Ltd., (“GNI Group”; TOKYO: 2160) has received a recommendation from the independent data monitoring committee (IDMC) reviewing the F351 drug candidate’s Phase II liver fibrosis trial in China to end the enrollment of new patients in the trial based on positive efficacy results achieved to date. Currently, 175 patients out of an original 240 patient target have been enrolled in the trial. In 2015 GNI Group initiated the Phase II trial to study the safety and efficacy of F351 in the treatment ...
DELAWARE--(BUSINESS WIRE)-- Cullgen Inc, (“Cullgen” or the “Company), a drug discovery company focused on development of drug candidates using uSMITE™ (ubiquitin mediated small molecule induced target elimination), announced that Dr. Timothy Heffernan and Dr. Michele Pagano have joined the Company’s Scientific Advisory Board (SAB). Cullgen’s current SAB also includes Drs. Stephen Frye, Lisa Carey, and Peter Jackson. Dr. Timothy Heffernan is currently the Executive Director and Head of Oncology Research at the Institute for Ap...
TOKYO--(BUSINESS WIRE)-- GNI USA, Inc., a wholly-owned subsidiary of GNI Group Ltd. (TOKYO:2160), announced the first subject was dosed in the F351 Phase I clinical trial taking place in New Jersey, USA. The primary objective of this trial is to understand the pharmacokinetics and safety of F351 in a diverse ethnic population to supplement the previous Phase I results obtained in China. A total of 48 subjects will be enrolled in the trial and it is expected to be completed by the second half of 2018. About F351 ...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.